Sage Therapeutic Com (SAGE) Stock Price, Quote & News

Company Profile

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies;...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 299 8380

Fax: 617 299 8379

Website: www.sagerx.com

Address:

55 Cambridge Parkway, Cambridge, United States

StocktwitsNews Jun. 23 at 2:54 AM

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms $SAGE $SUPN $BIIB https://stocktwits.com/news/equity/markets/sage-therapeutics-stock-jp-morgan-sees-8-downside-after-supernus-buyout-terms/chmP8riRR55

0 · Reply

DonCorleone77 Jun. 22 at 8:25 PM

$SAGE Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan JPMorgan analyst Anupam Rama lowered the firm's price target on Sage Therapeutics to $8.50 from $11 and keeps a Neutral rating on the shares. The firm cites the acquisition deal price by Supernus Pharmaceuticals for the target cut.

0 · Reply

anachartanalyst Jun. 20 at 8:01 PM

$SAGE https://anachart.com/wp-content/uploads/ana_temp/1750449706_soc-img.jpg

0 · Reply

Rage_Against_The_Machine Jun. 19 at 8:13 PM

Halper Sadeh investigates $SAGE's $8.50+$3.50 CVR sale to Supernus. While the deal offers exit liquidity, Sage's fundamentals remain shaky: Q1 revenue still 84% below 2023 levels, burning $81.7M cash. Market pricing assumes flawless deal execution - law firm scrutiny suggests potential turbulence ahead. https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-verv-sage-ctlp-colb-on-behalf-of-shareholders-302486497.html

0 · Reply

Unicorn2020 Jun. 17 at 10:20 PM

$SUPN A major competitor of $VNDA just paid approximately $795 million to $SAGE, about $12/share for its new depression drug, Zurzuvae - the first and only oral treatment for postpartum depression. Note that SAGE has $6.77/share of cash-in-hand and $0 debt. The CEO of VANDA, Mihael H. Polymeropoulos wants a better offer than $12? That's not going to happen "IF" he keeps throwing the company cash away on silly ads and new employee hirings. Stop the frivolous spending, egg head!

1 · Reply

ZacksResearch Jun. 17 at 6:50 PM

$SAGE getting scooped up in $795 million deal — is this SUPN’s breakout moment? SUPN is acquiring Sage Therapeutics and locking down rights to depression drug Zurzuvae, signaling a bold push into neuroscience. Full deal breakdown here 👉 https://www.zacks.com/stock/news/2507455/sage-to-be-acquired-by-supernus-pharmaceuticals-in-795-million-deal?cid=sm-stocktwits-2-2507455-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2507455_TEASER

0 · Reply

ZacksResearch Jun. 17 at 5:47 PM

$SAGE surges 35.4% on acquisition news! 🚀 Supernus Pharmaceuticals is set to acquire Sage Therapeutics at $8.50/share, with a potential total value of $12/share if sales milestones are hit through a contingent value right. This acquisition will grant $SUPN rights to SAGE’s new depression drug, Zurzuvae, boosting its diverse neuroscience portfolio. Discover the full deal details here 👉 https://www.zacks.com/commentary/2507455/sage-to-be-acquired-by-supernus-pharmaceuticals-in-795-million-deal?cid=sm-stocktwits-2-2507455-body&ADID=SYND_STOCKTWITS_TWEET_2_2507455_BODY

0 · Reply

JarvisFlow Jun. 17 at 2:40 PM

Truist Securities updates rating for Sage Therapeutics ( $SAGE ) to Hold, target set at 8 → 9.

0 · Reply

JarvisFlow Jun. 17 at 2:18 PM

HC Wainwright & Co. has adjusted their stance on Sage Therapeutics ( $SAGE ), setting the rating to Neutral with a target price of 12.

0 · Reply

Thestocktraderhubzee Jun. 17 at 2:17 PM

$SAGE HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $12 Price Target

0 · Reply

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

PHAT

Jun 18, 2025, 11:03 PM EDT - 6 days ago

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

SUPN

Jun 17, 2025, 2:22 PM EDT - 7 days ago

These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News

Jun 17, 2025, 10:00 AM EDT - 8 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect

Jun 17, 2025, 8:31 AM EDT - 8 days ago

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

RGC VERV

Jun 16, 2025, 5:31 PM EDT - 8 days ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.

SUPN

Jun 16, 2025, 7:42 AM EDT - 9 days ago

Sage Therapeutics Stock Soars 35% After Sale to Supernus. What We Know.

Jun 16, 2025, 7:14 AM EDT - 9 days ago

Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal

SUPN

Jun 15, 2025, 10:00 AM EDT - 10 days ago

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jun 12, 2025, 10:00 AM EDT - 13 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Stockholders to Learn More About the Investigation

Jun 10, 2025, 10:00 AM EDT - 15 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities Investigation

Jun 9, 2025, 8:30 AM EDT - 16 days ago

INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. and Encourages Long-Term Investors to Contact the Firm - SAGE

Jun 8, 2025, 10:00 AM EDT - 17 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation

Jun 5, 2025, 10:00 AM EDT - 20 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Connect

Jun 3, 2025, 10:00 AM EDT - 22 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out

Jun 1, 2025, 10:00 AM EDT - 24 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation

May 29, 2025, 10:05 AM EDT - 27 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities Investigation

May 27, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the Investigation

May 25, 2025, 10:00 AM EDT - 4 weeks ago

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 22, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Connect

May 18, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Reach Out

May 1, 2025, 10:00 AM EDT - 7 weeks ago

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 29, 2025, 10:33 PM EDT - 2 months ago

Sage Therapeutics, Inc. (SAGE) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 4:05 PM EDT - 2 months ago

Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

Apr 9, 2025, 5:34 AM EDT - 2 months ago

Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag

BIIB

Apr 6, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Reach Out

Mar 4, 2025, 4:15 PM EST - 4 months ago

Sage Therapeutics Announces R&D Leadership Transition

Feb 11, 2025, 9:29 PM EST - 4 months ago

Sage Therapeutics, Inc. (SAGE) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 4:05 PM EST - 4 months ago

Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates

Jan 28, 2025, 4:30 PM EST - 5 months ago

Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Jan 27, 2025, 9:20 AM EST - 5 months ago

Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen's Unsolicited Acquisition Proposal

Jan 13, 2025, 10:40 AM EST - 5 months ago

Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid

BIIB

Jan 13, 2025, 9:38 AM EST - 5 months ago

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?

Jan 13, 2025, 7:24 AM EST - 5 months ago

Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen

BIIB

Jan 12, 2025, 6:00 PM EST - 5 months ago

Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference

Jan 10, 2025, 6:49 PM EST - 5 months ago

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen

BIIB

Jan 8, 2025, 6:30 AM EST - 6 months ago

Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

Nov 26, 2024, 7:00 AM EST - 7 months ago

Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 10:36 AM EST - 7 months ago

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder

Nov 20, 2024, 7:34 AM EST - 7 months ago

Sage Therapeutics to end Huntington's disease trial after key therapy fails again

Nov 20, 2024, 6:58 AM EST - 7 months ago

Sage Therapeutics scraps development of rare disease drug after it fails mid-stage study

Nov 20, 2024, 6:30 AM EST - 7 months ago

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease

Oct 29, 2024, 9:35 PM EDT - 8 months ago

Sage Therapeutics, Inc. (SAGE) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 4:05 PM EDT - 8 months ago

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates

StocktwitsNews Jun. 23 at 2:54 AM

0 · Reply

DonCorleone77 Jun. 22 at 8:25 PM

0 · Reply

anachartanalyst Jun. 20 at 8:01 PM

$SAGE https://anachart.com/wp-content/uploads/ana_temp/1750449706_soc-img.jpg

0 · Reply

Rage_Against_The_Machine Jun. 19 at 8:13 PM

0 · Reply

Unicorn2020 Jun. 17 at 10:20 PM

1 · Reply

ZacksResearch Jun. 17 at 6:50 PM

0 · Reply

ZacksResearch Jun. 17 at 5:47 PM

0 · Reply

JarvisFlow Jun. 17 at 2:40 PM

Truist Securities updates rating for Sage Therapeutics ( $SAGE ) to Hold, target set at 8 → 9.

0 · Reply

JarvisFlow Jun. 17 at 2:18 PM

HC Wainwright & Co. has adjusted their stance on Sage Therapeutics ( $SAGE ), setting the rating to Neutral with a target price of 12.

0 · Reply

Thestocktraderhubzee Jun. 17 at 2:17 PM

$SAGE HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $12 Price Target

0 · Reply

JarvisFlow Jun. 17 at 12:30 PM

Canaccord Genuity has adjusted their stance on Sage Therapeutics ( $SAGE ), setting the rating to Hold with a target price of 8 → 8.5.

0 · Reply

Bombay55 Jun. 17 at 11:08 AM

$SRPT its interesting M&A activity in biotech recently $VERV $SAGE $CVAC

0 · Reply

dikbukiss Jun. 17 at 12:18 AM

Today’s top 5 in my portfolio $SAGE $SMCL $AGEN $GBIO $JDST

1 · Reply

cubie Jun. 16 at 7:18 PM

$SRPT $SAGE $VKTX thanks for confirming how useless lemming analysts are. stonk goes up, they all raise price targets, stonk goes down, they all cut price targets lol. so fkng useless! and noobtards who think their any good are just next level dum dums. really!

0 · Reply

topstockalerts Jun. 16 at 7:16 PM

$SAGE let's see some action in the power hour...🍾🍾

0 · Reply

cubie Jun. 16 at 7:13 PM

$SRPT holy cow 15000% for bears huh, if permabulls knew to buy poots from time to time 🤫😅🙄smh. its a spec bio that was in $100S just like $SAGE just like $VKT the lemming anaylsts had price targets in 100s then, what their price targets now?🤔😒 again lemmings are useless! Lesson for today for those who dont this basic already smh

0 · Reply

Steve_TheBull_Rogers Jun. 16 at 7:13 PM

$SAGE Called it back in January Congrats on the buy out longs who took the lows

0 · Reply

cubie Jun. 16 at 6:30 PM

$SAGE $VKTX tell me what price targets lemming analyst had for $SAGE wen that spec bio was in $90S? anyone who mentions lemmings as their reason to hold a stonk just confirm they are true noobs. thats all. useless as the lemming analysts themselves. cubie teaches

1 · Reply

benny2800 Jun. 16 at 6:05 PM

$SAGE why doesnt this move

0 · Reply

topstockalerts Jun. 16 at 5:53 PM

$SAGE strong watch at these levels👀...👀

0 · Reply

prismmarketview Jun. 16 at 5:28 PM

$BATL, $SAGE, $HUSA, $TSSI, $GALT Geopolitical tensions and acquisition buzz are stirring up the markets today. Defense and biotech stocks are making bold moves as investors respond to global shifts and strategic deals. https://prismmarketview.com/prism-mid-day-movers-geopolitical-risk-and-aquisition-activity-drive-index-action/

0 · Reply

ChromeOnTheWheels Jun. 16 at 4:54 PM

$CPRX $ESPR $GERN $SAGE Glad I stayed long SAGE!

0 · Reply

Market Cap	582.38M
Revenue (ttm)	41.24M
Net Income (ttm)	-400.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-971.56%
Debt to Equity Ratio	0.00

Volume	1,287,000
Avg Vol	1,520,970
Day's Range	N/A - N/A
Shares Out	62.62M
Stochastic %K	96%
Beta	0.18
Analysts	Sell
Price Target	$8.47